Will partner with innovators to unlock their manufacturing potential by capitalizing on best-in-class manufacturing technologies and bioprocessing expertise
Isolates hundreds of virus-neutralizing, human antibodies; will prepare manufacturing-ready cell lines so that clinical-scale production can begin immediately.
Clinical study will explore the potential of TJM2, a mAb against Cytokine Release Syndrome, which is an overreaction of the immune system caused by inflammation
Designed to adopt both large scale commercial manufacturing using disposable bioreactors and next-gen continuous bioprocessing manufacturing technology